ClinicalTrials.gg
TerminatedNCT02807961Updated Oct 22, 2019

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

A Phase 1 interventional study of ELX-02 and Placebo in Genetic Diseases and Nonsense Mutations, sponsored by Eloxx Pharmaceuticals, Inc.. Terminated. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Transferred study to Antwerp, Belgium

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is the first study in humans of ELX-02, an advanced synthetic aminoglycoside optimized as a translational read-through drug (TRID) for the treatment of genetic conditions caused by nonsense. mutations. This is a classical Phase 1a study designed as a randomized, double-blinded, placebo-controlled, single dose escalation to evaluate the safety, tolerability and pharmacokinetics of ELX-02 in healthy adult volunteers.

02

Conditions studied

  • Genetic Diseases
  • Nonsense Mutations

Keywords

  • Translational read through
03

In context

Genetic Diseases, Inborn

584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.

This study's enrollment of 42 is close to the median of 41 across 306 interventional studies indexed under Genetic Diseases, Inborn.

Browse Genetic Diseases, Inborn studies →

Lead sponsor

Eloxx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study:

  1. Be able and willing to provide written indicating that the subject has been informed of all pertinent aspects of the study.
  2. Be willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Healthy female subjects and/or male subjects who, at the time of Screening, are between the ages of 18 and 45 years, inclusive.

    Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead and clinical laboratory tests.

  4. Female subjects of non must meet at least one of the following criteria: status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; post-menopausal status will be confirmed by a serum FSH level, Have undergone a documented hysterectomy and/or bilateral oophorectomy, Have medically confirmed ovarian failure Female subjects of non-childbearing potential must agree to undergo pregnancy test at Screening.

    All other female subjects (including females with tubal ligations) will be considered to be of childbearing potential and may be enrolled if they have negative pregnancy tests on Screening and admission days and agree to use a reliable method of for two weeks (14 days) before and four weeks (28 days) after dosing.

    Female subjects of childbearing potential must agree to undergo repeated pregnancy tests.

    Reliable methods of contraception include: Abstention from sexual intercourse, Established use of oral, inserted, injected, implanted or transdermal hormonal methods of contraception (provided the subject plans to remain on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness), Copper-containing intrauterine device

  5. Male subjects must be willing to use an effective method of contraception during the course of the study until 28 days after drug administration. These include condom, having undergone a vasectomy or abstain from sexual intercourse.
  6. Be on no medications with potential to impair renal function, e.g., NSAIDs, or with ototoxic potential, e.g., quinine or salicylates.
  7. Non-smoking and no use of any tobacco or nicotine products (by declaration) for a period of at least 6 months prior to Screening visit.
  8. Normal renal function ( GFR > 60 mL/min) based on serum creatinine concentration.
  9. Negative , or Ab serology tests at Screening.
  10. No personal history of hearing loss, tinnitus, vertigo, imbalance and unsteadiness.
  11. Normal Screening auditory and vestibular assessments.
  12. (BMI) of 19.0 to 30.0 Kg/m2.

Exclusion criteria

Exclusion Criteria

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Subjects who are site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are the Sponsor employees directly involved in the conduct of the study.
  2. Participation in another clinical trial within 6 months prior to dosing (calculated from the previous study's last doing day). If the previous trial involved agents with delayed effects or prolonged metabolism, a 12 months interval is required.
  3. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies,). This includes any acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ELX-02 administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  4. A positive urine drug screen (cannabinoids, amphetamines, benzodiazepines, and opiates), at Screening and on admission.
  5. History of regular alcohol consumption (by declaration) exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of Screening. A positive alcohol breath test on admission.
  6. Screening supine blood pressure (BP) ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP exceeds protocol-required limits, BP measurement should be repeated for up to two more times and the last BP value should be used to determine the subject's eligibility.
  7. Screening supine 12-lead demonstrating >450 msec for men or >470 msec for women, or a QRS interval >120 msec.
  8. Subjects with ANY abnormalities in clinical laboratory tests at Screening, considered by the Investigator as clinically relevant. In particular, subjects with , AST and total ≥ 1.5 will be excluded.
  9. Pregnant or breastfeeding female subjects.
  10. Use of prescription or nonprescription drugs, vitamins, herbal and/or dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to administration of ELX-02. As an exception, acetaminophen/paracetamol may be used at doses of ≤ 2 g/day. Aspirin and NSAIDS should not be administered within 1 week of study dose. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the Sponsor.
  11. Subjects who donated blood or received blood or plasma derivatives in the 3 months preceding study drug administration.
  12. Known allergy or to any drug and/or to any of the of ELX-02.
  13. Subjects with an inability to communicate well with the Investigators and CRC staff (e.g., language problem, poor mental development).
  14. Subjects with any acute medical situation (e.g. acute infection) within 48 hours prior to Day 1, which is considered of significance by the Principal Investigator.
  15. Subjects with any history of ear disease or surgeries, dizziness or ongoing tinnitus.
  16. Subjects with any abnormality on physical examination by an ENT specialist at screening that indicates the presence of a vestibular pathology, conductive hearing loss or balance problem.
  17. Subjects with audiometry results as follows: any pure-tone threshold >25dB, inter-ear difference in any frequency of ≥ 20dB, word recognition score (discrimination) \<92%.
  18. Abnormal ENG/VNG [as indicated by a cumulative response of \<12 degrees to caloric testing (response to warm and cold stimulation united) in either ear] or abnormal c/v HIT.
  19. DHI-H score >16
  20. THI-H score >14
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo comparator arm

    Drug: Placebo

  • Active comparator
    Active treatment

    ELX-02, active comparator

    Drug: ELX-02

Interventions

  • DrugELX-02

    Synthetic aminoglycoside

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Incidence and characteristics of adverse events occurring following single doses of ELX-02

    Time frame: 0-10 days

  2. Pharmacokinetics

    The following PK parameters will be calculated based on ELX-02 plasma concentrations: Cmax, Tmax, AUC24h, AUCinf, AUC144h, t½, mean residence time (MRT), volume of distribution (Vd), clearance (CL), absolute bioavailability (F) and an estimation of ELX-02 dose linearity of PK parameters. The following parameters will be calculated based on ELX-02 urine concentrations: urinary mass excretion of ELX-02 (in mass and %dose) and cumulated urinary excretion (in % dose) for each collection interval and total renal clearance. The following parameters will be calculated from the individual urine drug concentrations: Ae, Ae0-12h, Ae12-24h, Ae24-48h, Ae0-48h, fe.

    Time frame: 0-10 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Feb 2017, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 21, 2016
StartActual
Jul 2016
Primary completionActual
Feb 2017
CompletionActual
May 2017
Last update
Oct 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02807961
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jul 2016
Primary completion
Feb 2017
Completion
May 2017
Last update
Oct 22, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ELX-02

Start the discussion